Welcome to LeMaitre Vascular Quarter Two 2026 Financial Results Conference Call. As a reminder, today's call is being recorded. At this time, I would like to turn the call over to Mr. Dorian LeBlanc, Chief Financial Officer of LeMaitre Vascular. Please go ahead, sir. Good afternoon, thank you for joining us for our Q2 2026 conference call. With me on today's call is our CEO, George LeMaitre, and our President, Dave Roberts. Before we begin, I'll read our safe harbor statement. Today we will make some forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, the accuracy of which is subject to risks and uncertainties. Wherever possible, we will try to identify those forward-looking statements by using words such as believe, expect, anticipate, pursue, forecast, might, and similar expressions. Our forward-looking statements are based on our estimates and assumptions as of today, August 4th, 2026, and should not be relied upon as representing our estimates or views on any subsequent date. Please refer to the cautionary statement regarding forward-looking information and the risk factors in our most recent 10-K and subsequent SEC filings, including disclosure of the factors that could cause results to differ materially from those expressed or implied. During this call, we will discuss non-GAAP financial measures such as organic sales growth. A reconciliation of GAAP to non-GAAP measures discussed in this call is contained in the associated press release and is available in the investor relations section of our website, www.lemaitre.com. I'll now turn the call over to George LeMaitre. Thanks, Dorian. Artegraft grew 34% in Q2, accounting for 21% of sales. Grafts up 23%, shunts up 18%, and patches up 4%. Each posted records, as did EMEA up 18%, APAC up 18%, and the Americas up 5%. Sales grew 10% organically in Q2, 7% from price, and 3% from units. Catheters were down 11% in Q2 due to recall-driven overstocking in the year-earlier quarter. Excluding catheters, Q2 2026 organic growth was 12%, 7% from price and 5% from units. Notably, we underperformed our Q2 2026 sales guidance by $1.1 million for three reasons, each with roughly the same impact in the quarter. The strengthening of the dollar after we gave guidance on May 5th, the impact of the Middle East war continued to delay export revenues, and cardiac allograft sales have been hampered by supply. Our guidance reflects these three items continuing to hamper sales in H2. Turning to the positive, Artegraft has become our fastest and largest product, and we're investing in the product in several ways. Number one, more international approvals. Number two, longer sizes for leg bypasses, particularly for Europe. Number three, building out our sales force and our commercial infrastructure. International Artegraft sales advanced sequentially from $2.1 million in Q1 to $2.8 million in Q2. We now expect sales of $11 million in 2026 versus $4 million in 2025. Artegraft's approvals were received in Vietnam, Morocco, and Turkey in Q2. We are now approved in 56 countries. We also expect three large approvals in 2027, Korea, Brazil, and India. In July, we met face-to-face with Japan's PMDA. The initial response was positive. We might receive approval for the AV indication by 2029/2030 without a clinical trial. Canada approved Artegraft last year. The launch is set to occur this September. We're also working to make longer Artegrafts available. Because European surgeons use Artegraft for leg bypasses, our longest Artegraft, which is 50 centimeters, is now in high demand. The Artegraft packaging tube is just 53 centimeters long. We plan to make approval filings for longer tubes in the U.S. and Europe in Q4 2026, for sales of these longer bovine grafts could start in H2 2027. Here's an update on the QuickStitch project. We made a pre-submission filing to the FDA for this indication. Unfortunately, we now believe that a clinical trial is likely. If we like to follow this path, the timeline would be measured in years, not quarters. As a follow-up to the 2025 warning letter, the FDA re-audited our New Jersey facility in June 2026. At this audit, we believe that we adequately addressed three-fourths of their 2025 observations. On June 25th, the FDA provided us an additional set of quality systems observations. As per standard practice, we responded on July 16th. The observations from these audits have not disrupted our ability to produce, ship, or invoice. As for RFA, allograft revenues grew 17% in Q2. We now distribute these cadaver tissues in four countries: the U.S., Canada, the U.K., and Germany. German surgeons have recently performed three implants. Our German sales force reports high levels of interest from German surgeons due to the quality and availability of our tissues. In Ireland, we have just responded to our first set of questions from the Irish Tissue Authority. We await an inspection of our Dublin facility. Current expectations are for an Irish approval in H1 2027. Long term, the Dublin facility is expected to be used for Irish as well as Pan-European RFA distribution. Here's the timeline for when we expect to begin distributing tissues in several other countries. H1 2027, Austria, Holland, and Spain. H2 2027, Australia and Switzerland. As always, we continue to hire sales reps and build out our commercial infrastructure. We ended Q2 with 163 sales reps. We still plan to end the year with 170 to 180 reps. Nine reps have signed and are set to start in Q3. 13 requisitions are currently open. In July, we signed a Polish go-direct term sheet. We expect to sell direct to hospital from a Warsaw warehouse this December. In addition to Dublin and Warsaw, we have five other warehouse projects underway. Our primary warehouse has tripled and moved to Billerica, Massachusetts. Madrid has doubled and now ships all products. Paris is doubling in Q3 and will ship all products. Toronto is moving and tripling in Q3. Finally, Hereford, U.K., is moving to the London area in Q4. In total, that's seven new or larger warehouses opening in 2026/2027. We believe these infrastructure projects will help make a tighter connection between LeMaitre and its worldwide hospital customers. Higher ASPs, geographic expansion, and disciplined spending produced 10% sales growth and 23% EPS growth in Q2 2026. Our 29% op margin in Q2, as well as our 17% ROE, underscores the strength and profitability of our business. Full year guidance implies 11% organic sales growth and 21% EPS growth. I'll now turn the call over to Dorian. Thanks, George. LeMaitre's Q2 organic revenue growth of 10%, consisting of 7% price growth and 3% unit growth, was impacted by the Q2 2025 stocking orders following our package relating catheter recall. As George noted, excluding catheters, organic growth across the remaining portfolio was 12%, consisting of 7% price and 5% unit growth. The 5% unit growth was highlighted by the strong unit growth of Artegraft and Cardiac RestoreFlow. In Q2 2026, gross margin was 72.1%. The 210 basis point increase year-over-year was driven primarily by higher ASPs, reduced shipping costs, and positive product mix, supported in particular by growing high-margin Artegraft sales. We remain on track to transfer tissue processing from our Fox River Grove facility in Illinois to our Burlington, Massachusetts headquarters before the end of the year, and we have already yielded tissue in Burlington. In addition, we began shipping our core devices in June from our new 34,000 sq ft high bay warehouse in Billerica to U.S. domestic customers and our international subsidiaries and distributors. Operating expenses in Q2 2026 were $34.4 million, an increase of 5% versus Q2 2025, resulting from continued hiring restraint as full-time employees increased marginally from 658 at June 30, 2025, to 660 at June 30, 2026. We do anticipate continued 2026 investment in expanding our global sales force, including the new sales reps joining in Q3. Q2 operating income was a record $20.4 million, up 26% and resulting in an operating margin for the quarter of 29%. Net income increased 24% year-over-year to $17.1 million, and fully diluted EPS was $0.74, up 23%. Our fully diluted EPS calculation for Q2 2026 triggered the if converted accounting for our convertible debt, increasing the fully diluted share count to 24.5 million for the basis of this calculation. We ended Q2 2026 with $376 million in cash and securities, an increase of $9 million in the quarter. Cash from operations generated $16 million in Q2. We incurred $2.3 million in capital expenditures and paid $5.7 million in dividends to shareholders. We have updated our full year revenue guidance to $276.3 million and 11% reported revenue growth. Expected reported revenue has declined as we updated our FX assumptions for the strengthening U.S. dollar since our February and May guidance. We have reduced full year organic revenue growth from 12% to 11% to reflect our Q2 results and the revenue impact related to our export business and slowing growth for RFA, largely due to anticipated supply constraints. We anticipate full year gross margin of 72.4%, a 200 basis point improvement from adjusted 2025. Full year operating income of $76.8 million, resulting in a 28% operating margin for 2026 and an op inc increase of 19% from adjusted 2025. We have also updated our guidance on fully diluted earnings per share to $2.89, up 21% from adjusted 2025. Our guidance implies a fourth consecutive year of strong double-digit revenue growth and 20%+ EPS growth. We will now take questions. Thank you. At this time, we will conduct a question and answer session. As a reminder, to ask a question, you will need to press star one one on your telephone and wait for your name to be announced. To withdraw your question, please press star one one again. Please stand by while we compile the Q&A roster. Our first question comes from the line of Michael Sarcone with Jefferies. Your line is now open. Hey, good afternoon, and thanks for taking the question. I guess, George, just to start, you gave us the update on the Quick Stick claim, we have got this timeline measured in years now, I guess, can you give us a little more color on how you are thinking about allocating resources to that effort and just any updated thoughts on what you are going to do there? Sure. We definitely see that as a nice piece of the market, Mike. By the way, thanks for your question. Appreciate it. I think the news is fresh enough here that we just need to sit back and decide what to do next here. We are not really a clinical trial company historically, but we do have these aspirations to get a little bit more R&D focused. I think it will take us a little time to figure that out, but we do acknowledge it is an important piece of the market, particularly in the U.S. Got it. Thanks, George. Just on the RestoreFlow supply constraints, I guess, how are you thinking about next steps here and maybe any timelines for when you could see some relief on those constraints? Sure. As you can imagine, we're running around like crazy trying to solve this. I think when you're dealing in cadaver tissues, there are always threats of supply around you. There's a set of four or five to-dos that we're not going to bore you with today, that we're in the middle of trying to do. If you want to think of this positively, when we first took over this company in 2016 for the first five years, we had tremendous difficulty having enough supply of the peripheral vascular tissues, the veins and the femoral arteries and such. We've definitely solved that. We feel really good about that. This is sort of the next frontier. I always say this to the sales force, which is 95% of your products are good to go here. We have ample supply, and they always talk about the one that doesn't. We want to get rid of it because it's tiring to sit there and listen to it from the sales force as much as we want the sales to come out. Hey, Mike, this is Dorian. Maybe just to add on that. Cardiac allografts were up 39% quarter-on-quarter. We're talking about a business that's performing very well. Just maybe the growth rate slowing a bit from where we anticipated. One of the big things, of course, that we're doing on supply is to move that processing here to Burlington, Massachusetts, where we're all closer to it. I think those are two important things to kind of wrap up the question. Great. Thanks to both of you. Thanks a lot. Thank you. Our next question comes from Brett Fishbin. Hey, guys. Thank you. Sorry about that. Go ahead. All right. Thanks so much, guys, for taking the questions. Just had a quick one first on Q2. The geographical performance versus our model at least looked pretty good in Europe and in Asia. Americas was a little bit softer than expected. Was hoping you could just touch on what you're seeing in the Americas region, just given some of the mixed reads on procedural growth this quarter domestically, or if that was mostly driven by the catheter issue. I would say we should start with the catheter issue, which is, first of all, if you X- out the Aziyo issue, we've all forgotten about that, but we used to distribute Aziyo way back when it was in Q2 of 2025. You get it to a 6% organic number for the Americas. Then if you strip out the catheter topic, again, you can go strip out stuff, right? But if you strip that out, that's a real thing. You get it to 8% organic in the Americas, it's probably feeling more normal to us that that's our business. Your second part of your question, Brett, was about the procedure volume, I think we tend not to lean on that in these phone calls about procedure volume. One specific reason we might not lean on it is the stuff we're reading about in the newspapers about the Affordable Care Act and all that, it's not really our customer. Our customers are 70-year-old men and women, and they're not Medicaid patients and things like that. We don't want to lean too hard on that. I think the internal issues, again, if you X out those two issues, you can get yourself to 8% organic growth for the quarter. Right. Great. Then just one follow-up from me. I think you talked a lot more today in the press release and prepared remarks about some of these warehouse expansions and the magnitude and number of them. Maybe if you could just elaborate a little bit more at a high level on this overall initiative, and if there's any long-term read into either margin expansion upside or working capital. Thank you so much. Right. Okay. Thanks for giving me the platform to talk about this. This is sort of one of my really serious initiatives inside the company called relocalization. Historically, we tried to address Europe just from Frankfurt because we're all excited about the EU and the Schengen zone and the euro as common currency. I would say, myself and our team, we've sort of debunked that over 20 years. In the last five years, we've gotten much more serious about a Spanish hospital wants to talk to a Spanish customer service rep located in Madrid with the product sitting right next to him or her and get it shipped directly for so many reasons. That's the hypothesis of relocalization, you can kind of see we've gone a bit hog wild with it, right? When Warsaw opens up, we're going to have seven offices in Europe, I believe. Maybe 15 years ago, it was just one in Frankfurt. We've really gone down this path. There's the outside reasoning or the larger rationale for it. What we're also finding, which we didn't expect to find, is shipping a package from Frankfurt costs $55 to the Madrid hospital, shipping a package from Madrid to the Madrid hospital costs $5. There's this huge shipping savings to go with Artegraft being so much bigger in Europe. Just to press forward on a point here. There's an explosion of gross margin going on over in Europe, I've never seen this in my career, but it's six points, five points, nine points year-over-year. Full points, not bps. It's been really satisfying to see even though we spent the money on these places, the gross margin's exploding over there for a number of reasons. I would say the focus of the success of the company in Q2 clearly was Europe, whether it be from a sales perspective or on a growth to profitability perspective. I think the profitability of that segment was up like 70% or something like that. It's really going nicely over there, it's sort of intertwined with that relocalization project. All right. Thank you so much, George. Super helpful color. Thanks, Brett. Thank you. Our next call comes from Rick Wise with Stifel. Your line's now open. Hi, this is Annie on for Rick. Thanks for taking our question. My first one is on Artegraft in Europe. When we spoke with you last, we kind of heard that Artegraft was seeing early success in these European countries with shorter sales cycles while the more tender-based countries were likely to come in further down the road. I guess, can you update us on where those tender processes stand today, and whether the updated back half outlook is going to depend on those wins converting before the year end? Okay. I think when we gave the Q1 call, we were a little bit like, "Well, is it going to be $10 million or what?" We were all talking about it, and we're happy to say Q2 seemed like a little bit better than we all expected over in Europe for Artegraft. We're thrilled about that. As to your specific question on the tender countries, I don't have a real angle on that. I will say that when it first started, let's call it Q3 and Q4 of 2025, it felt very much like a central Europe, I'm going to say Holland, Belgium, Germany, Austria thing. In the last three or four quarters, it definitely has spread out. It's become a big topic in France, Italy, and Spain, and a big topic in the U.K. The tender-driven markets of sort of the Nordics, when you talk about tenders over there, and in the Southern European markets, you feel like the Nordics may be a little slower, and the tender-driven markets of the south part of Europe are doing really well right now. Very well. It's helping the business post records every month and every quarter. Great. Thanks. Maybe just to follow up on the RFA supply constraint, maybe just generally about the longer-term opportunity outside the U.S. I'm curious if you have any plans to build out tissue processing OUS and what that might entail in terms of the timing, investment, and regulatory work there. Annie, it's Dave. It's a great question. It is something we think about on a long-term basis, I think we still have a long way to go in the U.S. to rationalize and improve our supply of cardiac tissue, especially here. I think we're focused on that in the near term. As Dorian mentioned, we're moving the processing from the Chicago area to Burlington. All the management will be concentrated here, and we are taking a few steps to improve the supply here. Certainly, as we see sales start growing OUS, that topic about supplying outside the United States becomes more relevant. I don't think it's a near-term project for the company at this point. Okay, great. Thanks for the color. Thank you. Our next question comes from the line of Danny Stauder with Citizens. Your line is now open. Great. Thanks for the questions. My first one, just want to focus on the guidance. If we're looking at the guide below the top line, gross margin was in line with the quarter. You raised it a bit for the full year, full year Operating Income guide was lowered by a bit more than this quarter's performance versus the quarterly guide. I guess really my question is just could you help us with some of those dynamics? Maybe it's simple as it's a function of lower sales base or some product mix, but just how should we think about these metrics moving in opposite directions in the back half and how we should think about them in our model? Thank you. Danny, it's Dorian. I think you're right on the decrease in Operating Income guidance is just directly dropping through from the revenue decline. Really that's a function of the three factors that George walked through in the prepared remarks, which is about a 1/3 of the miss for Q2 and a 1/3 of the change in guidance is purely related to FX. In our prepared remarks in Q2, I think we gave the euro rate that we were forecasting at 117. Of course, we exited the back half of June at 114, which hurt us in the quarter. It's come up a little bit to 115. That's about a 1/3 of the miss for Q2 and about a 1/3 of the change in guidance for Q3 and Q4. We do continue to just have this hangover on our export business from not being able to ship to the Middle East. We had $400,000 of orders ready to go here that just can't go out because of the conflict. We think again, that's probably something that's going to recur, and our export business overall is going to be down for the year if this doesn't resolve. The last third is really around while we did post a 39% growth rate on cardiac allografts, that growth curve coming down a little bit from our expectation really related to the supply. Those three factors kind of explain the Q2, and they're really the drivers of the change in guidance and the flow-through to the bottom line is the impact on Operating Income. Danny, maybe I could pick up a second half of your question, which I think you have in there, which is the bottom line and op expenses. I think as you compare H2 2026 to H2 2025, we were sort of in belt-tightening mode for those Q3 and Q4 of 2025. You're going to see, even though we haven't raised op expenses implicitly too much in this model here, it's going to look like a lot when we start coming around to the Q3 and Q4, particularly these sales reps being hired. That's something you're going to be noticing. The lack of op leverage is going to be driven a little bit by that. It was a tight-fisted company in Q3 and Q4 of last year, a little bit less so this year. We're seeing these projects we definitely want to get involved in, and so we're not sort of slowing down a little bit. Maybe that helps you on the bottom part of the guidance. No, that's great, callers. I appreciate that. Just one more focusing on the model. Dorian, I'll ask some of these of you again, but just as I think about EPS guide, are there any other dynamics beyond gross margin OpEx you already highlighted? I think last quarter you talked a little bit about tax and it being below your historical rate and some of that being due to the FDIIs. We saw it step up a little bit here in the quarter or so. How should we think about that in the back half and just anything else beyond or below the Operating Income line that we should think about as we model out here? Thank you. Yeah, sure. If you get below Operating Income, Danny, the put and the take is a little bit better yield on our invested cash. Yield curves come up a little bit, we're getting a little bit better earnings on that cash balance here in July versus where we were forecasting from May. On the effective tax rate, still getting that benefit from the FDII, the tax rate's really impacted by the discrete items, particularly around stock-based comp and the timing of option exercises. Fewer of that in Q2. Overall, for the blend of the year, our ETR for our guidance hasn't really changed too much, you're always going to see some variability, and I think we did caution in the call last quarter not to read into 20.3 as the long-term rate on the ETR. Yeah, probably a little higher than we anticipate in Q2, settling out more normalized throughout the year. Great. Thank you so much. Thank you. Our next question comes from the line of Jim Sidoti with Sidoti & Company. Your line is now open. Hi, good afternoon. Thanks for taking the questions. George, you've dealt with shortages for allografts before. What did you do then, and are you going to do something similar now? I would broaden that to, we pride ourselves. Thanks for the question, Jim. Great question. We pride ourselves on being a no backorder company. You've heard that from me a billion times over the years. We got to that with peripheral vascular, largely through huffing and puffing and sweating and figuring how to do stuff better. I think the big move here is going to be bringing the factory to Burlington, where it's near Trent, who's the head of ops, and Andrew, who's the head of regulatory, who's the guy in charge of approving all the stuff going out the door. I think that's the major move. We have AI in the background here with this new program called Donor IQ, we have put some constraints on because we were nervous about purchasing too much and only using a piece of this, and we've removed those constraints. There's a number of moves we can pull. I think it'll get better, and again, I think Dorian, in his initial response here, is pointing out, okay, but we still did grow the business 39% in the second quarter. There's still the cardiac business. There's still cause for, well, it's growing fast and they're missing that last piece of business by the lack of supply, but it's still a nice business. Yeah, we got to get down to work on that and fix that. It's on us. It sounds like you have a sufficient number of organ procurement people that you're dealing with to get the product. You just have to get better at processing it? I would say it's both. I do think we also consider it from time to time, bringing on more recovery groups. There's a limited number of those in the whole country, and we're already dealing with about half of them, but we do consider bringing more of them on from time to time. That might be an avenue as well. Okay. Just a quick one for Dave, just an update on the pipeline out there regarding acquisitions and what are you seeing? Yeah. Hi, Jim. Thanks for the question. It's a pretty active pipeline right now. Obviously, I don't usually disclose how many deals or the size of deals, but we are busy. In fact, we're adding a fourth member to the biz dev team this coming Monday. It is pretty busy. The target zone is what we've focused on the past, the roughly two dozen businesses in open vascular that are big enough for us to focus on, or expanding into cardiac surgery where We had about 13% of our Q2 revenue. The sweet spot, I'd say, is anywhere from $15 million-$150 million of revenue. Pretty active pipeline, building the team, and stay tuned. Great. Thank you. Thank you. As a reminder, to ask a question, you'll need to press star one one on your telephone and wait for your name to be announced. Our next question comes from the line of Keith Hinton with Freedom Capital Markets. Your line is now open. Great. Thank you. Apologies if this has already been addressed. I'm jumping around a little bit. Just in terms of catheters in the quarter, was that just simply a tough year-over-year comp, or is there any sort of durable change going on there, in terms of competitive dynamics? Sure, Keith. Thanks for the question. It is George. It is a big topic here in that in Q2 2025, we had a very big recall of a simple product line problem with our packaging on catheters. We pulled in a lot of product. Oddly, which does not always happen, the customer then went and did a bunch of hoarding. All of the customers around the world went and did a bunch of hoarding and bought a lot of devices. We had a huge catheter sales in Q2 last year. Now, coming around the bend here in Q2 this year, catheter sales were down 11%. If you strip the catheters out of the company's performance, instead of us showing up here today on this call with a 10% organic growth rate, you would have a 12% organic growth rate. It does make a big difference. We called that out in the press release, and we have called it out in this phone call as well. It is an important topic, and we do believe that it is transient and that you will not have that brutal comp again as you go into H2. Okay, great. Thanks for the clarification. Again, apologies if I missed this. Did you guys talk at all about the plans for Artegraft QuickStitch in terms of a potential trial there, trial design timeline, anything like that? We did. Keith, unfortunately, the news that we got from our FDA meeting, and we did address this in the prepared remarks. The FDA seems to be leaning, it is not for sure, but they seem to be leaning towards, "You have to go back and do a clinical trial for that." That puts us back at, gosh, should we go forward with this? It is a big investment, and it is an X-year timeline. We are still in the thinking it through phase of that project. Okay. Great. Thank you for the clarification. Again, apologies, jumping around to a bunch of calls. Thanks for the questions, Keith. Thank you. Our next question comes from Michael Petusky with Barrington Research. Your line is now open. Hi, Mike. It's George in Barrington. I think you're up if you're still hanging on to the call. Operator, he's usually pretty good about being here. Okay. Assume something happened here. You can either go on to next questions or wrap up the call, whatever you see is the right next move. Right. It looks like we have no further questions. Give me one moment. Yep. Ladies and gentlemen, that does conclude today's conference. I'd like to thank you for your participation, and you may now disconnect. Have a great day.